| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8f058a71899e153cedc18883bad5b31a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06026
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0806
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-10 |
| filingDate |
2008-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_593cc069172248037b3dfb4bcf214138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5e1f494c62c0d656e188238c9f58495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f60d32d2a56b8f53a96e81868232d58f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_469089da717bb10cac252f828b5ff1ef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9c036d3dffc95d6c3a91555307f2115
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce0056231cdc05d320ff20517a7bfdfd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6dd4bac3a34eb5cd7013947813f7ee62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5bd11d99d570ff357089912a19ba6045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_feba393810aee3c80158ee295b2fc995 |
| publicationDate |
2009-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BG-110141-A |
| titleOfInvention |
GALANTAMINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE |
| abstract |
The invention relates to novel compounds which are galanthamine derivatives, to processes for their preparation and to their use for the prophylaxis and / or treatment of neurodegenerative diseases, including senile dementia and Alzheimer's disease. The novel galanthamine derivatives according to the invention combine two effects: inhibition of acetylcholinesterase and butyrylcholinesterase activity due to the galanthamine molecule and inhibition of gamma-secreting activity inherent in the peptide fragment. |
| priorityDate |
2008-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |